Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
暂无分享,去创建一个
E. D. de Vries | E. de Vries | J. Kosterink | J. Gietema | W. T. van der Graaf | D. V. van Veldhuisen | P. L. Jager | D. Sleijfer | M. L. Lub-de Hooge | P. Perik | M. D. de Korte | W. V. D. van der Graaf | S. Jonkman
[1] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[3] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[4] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Hess,et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease. , 2005, Clinical laboratory.
[6] J. Bart,et al. Preclinical characterisation of 111In‐DTPA‐trastuzumab , 2004, British journal of pharmacology.
[7] P. Regitnig,et al. Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas , 2004, The Journal of pathology.
[8] Tanja Fehm,et al. HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[9] W. Lichtenegger,et al. Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™) , 2003, Breast Cancer Research and Treatment.
[10] S. Takekoshi,et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. , 2003, International journal of oncology.
[11] J. Bartlett,et al. The clinical evaluation of HER‐2 status: which test to use? , 2003, The Journal of pathology.
[12] Carmen Birchmeier,et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] Susumu Minamisawa,et al. ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.
[14] D. Sawyer,et al. Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity , 2002, Circulation.
[15] B. Wörmann,et al. Trastuzumab and breast cancer. , 2001, The New England journal of medicine.
[16] H. Moch,et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.
[17] M. P. van den Berg,et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[19] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[20] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[21] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[22] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.